FDA Sends Warning Letters To Two Chinese Producers Of Adulterated Heparin
This article was originally published in The Pink Sheet Daily
Executive Summary
Could prosecution be the next step? .
You may also be interested in...
Amphastar Lawsuit Over Heparin Shipments Suggests Lovenox ANDA Approval May Be Far Off
Allegations in Amphastar Pharmaceuticals’ lawsuit over FDA detention of heparin raw ingredient shipments suggest approval of its enoxaparin ANDA, the generic of Sanofi-Aventis’ low-molecular weight heparin Lovenox, is far from imminent.
Amphastar Lawsuit Over Heparin Shipments Suggests Lovenox ANDA Approval May Be Far Off
Allegations in Amphastar Pharmaceuticals’ lawsuit over FDA detention of heparin raw ingredient shipments suggest approval of its enoxaparin ANDA, the generic of Sanofi-Aventis’ low-molecular weight heparin Lovenox, is far from imminent.
USP Revised Heparin Testing Standards Take Effect Oct. 1
USP also establishes collaborative relationships with Chinese organizations following the adverse events from Chinese-sourced contaminated heparin.